SA109300394B1 - ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها - Google Patents
ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها Download PDFInfo
- Publication number
- SA109300394B1 SA109300394B1 SA109300394A SA109300394A SA109300394B1 SA 109300394 B1 SA109300394 B1 SA 109300394B1 SA 109300394 A SA109300394 A SA 109300394A SA 109300394 A SA109300394 A SA 109300394A SA 109300394 B1 SA109300394 B1 SA 109300394B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- compound
- isoquinolin
- thiazolo
- hydroxy
- atoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7385708P | 2008-06-19 | 2008-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA109300394B1 true SA109300394B1 (ar) | 2013-01-22 |
Family
ID=41087350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA109300394A SA109300394B1 (ar) | 2008-06-19 | 2009-06-17 | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8299090B2 (https=) |
| EP (2) | EP2896626A1 (https=) |
| JP (2) | JP5564495B2 (https=) |
| AR (1) | AR072265A1 (https=) |
| AU (1) | AU2009260060B2 (https=) |
| CA (1) | CA2728454C (https=) |
| DK (1) | DK2303895T3 (https=) |
| ES (1) | ES2530815T3 (https=) |
| HK (1) | HK1212698A1 (https=) |
| SA (1) | SA109300394B1 (https=) |
| TW (1) | TWI471329B (https=) |
| WO (1) | WO2009155402A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA109300394B1 (ar) * | 2008-06-19 | 2013-01-22 | ويث | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
| WO2009155413A1 (en) | 2008-06-19 | 2009-12-23 | Wyeth | Thienyl- and furanyl-isoquinolinones and methods for using them |
| JP2014520776A (ja) | 2011-07-04 | 2014-08-25 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 植物における非生物的ストレスに対する活性薬剤としての置換されているイソキノリノン類、イソキノリンジオン類、イソキノリントリオン類およびジヒドロイソキノリノン類または各場合でのそれらの塩の使用 |
| ES2562903T3 (es) * | 2011-07-13 | 2016-03-09 | Santen Pharmaceutical Co., Ltd | Nuevo compuesto que tiene actividad inhibidora de PARP |
| AU2016296905B2 (en) | 2015-07-23 | 2018-07-05 | Centre National De La Recherche Scientifique | Use of a combination of Dbait molecule and parp inhibitors to treat cancer |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| CA3092779A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN121398822A (zh) | 2023-06-21 | 2026-01-23 | 四方生物科学有限公司 | 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2963332D1 (en) * | 1978-05-26 | 1982-09-02 | Lepetit Spa | Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof |
| ITMI20002358A1 (it) * | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| TW200412959A (en) | 2002-11-22 | 2004-08-01 | Mitsubishi Pharma Corp | Isoquinoline compounds and medicinal use thereof |
| US7696255B2 (en) | 2005-08-01 | 2010-04-13 | Wietek Holding Gmbh | Process for the recycling of plastics |
| EP2069351B1 (en) | 2006-06-20 | 2015-10-28 | AbbVie Inc. | Pyrazoloquinazolinones as parp inhibitors |
| SA109300394B1 (ar) * | 2008-06-19 | 2013-01-22 | ويث | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
| WO2009155413A1 (en) | 2008-06-19 | 2009-12-23 | Wyeth | Thienyl- and furanyl-isoquinolinones and methods for using them |
-
2009
- 2009-06-17 SA SA109300394A patent/SA109300394B1/ar unknown
- 2009-06-18 ES ES09767711T patent/ES2530815T3/es active Active
- 2009-06-18 JP JP2011514801A patent/JP5564495B2/ja not_active Expired - Fee Related
- 2009-06-18 AU AU2009260060A patent/AU2009260060B2/en not_active Ceased
- 2009-06-18 EP EP14185672.4A patent/EP2896626A1/en not_active Withdrawn
- 2009-06-18 DK DK09767711.6T patent/DK2303895T3/en active
- 2009-06-18 CA CA2728454A patent/CA2728454C/en active Active
- 2009-06-18 WO PCT/US2009/047767 patent/WO2009155402A1/en not_active Ceased
- 2009-06-18 US US12/487,247 patent/US8299090B2/en not_active Expired - Fee Related
- 2009-06-18 EP EP09767711.6A patent/EP2303895B1/en active Active
- 2009-06-19 AR ARP090102266A patent/AR072265A1/es active IP Right Grant
- 2009-06-19 TW TW98120713A patent/TWI471329B/zh not_active IP Right Cessation
-
2012
- 2012-10-18 US US13/655,082 patent/US8906935B2/en active Active
-
2014
- 2014-03-28 JP JP2014067493A patent/JP2014122242A/ja not_active Withdrawn
- 2014-11-07 US US14/535,877 patent/US9265769B2/en active Active
-
2016
- 2016-01-21 HK HK16100665.6A patent/HK1212698A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2303895A1 (en) | 2011-04-06 |
| AU2009260060A1 (en) | 2009-12-23 |
| AR072265A1 (es) | 2010-08-18 |
| WO2009155402A1 (en) | 2009-12-23 |
| US20150133443A1 (en) | 2015-05-14 |
| HK1212698A1 (en) | 2016-06-17 |
| EP2303895B1 (en) | 2014-09-24 |
| US8906935B2 (en) | 2014-12-09 |
| JP2011525185A (ja) | 2011-09-15 |
| TWI471329B (zh) | 2015-02-01 |
| US8299090B2 (en) | 2012-10-30 |
| AU2009260060B2 (en) | 2015-01-22 |
| JP2014122242A (ja) | 2014-07-03 |
| US20130059843A1 (en) | 2013-03-07 |
| TW201002725A (en) | 2010-01-16 |
| CA2728454A1 (en) | 2009-12-23 |
| DK2303895T3 (en) | 2015-01-12 |
| HK1156310A1 (en) | 2012-06-08 |
| JP5564495B2 (ja) | 2014-07-30 |
| US9265769B2 (en) | 2016-02-23 |
| US20090318442A1 (en) | 2009-12-24 |
| ES2530815T3 (es) | 2015-03-05 |
| CA2728454C (en) | 2017-01-17 |
| EP2896626A1 (en) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA109300394B1 (ar) | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها | |
| EP3416964B1 (en) | 6-oxo-n-(1-(benzyl)-1h-pyrazol-4-yl)-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer | |
| US20210188808A1 (en) | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | |
| US10654867B2 (en) | Heteroaryl estrogen receptor modulators and uses thereof | |
| JP2023522045A (ja) | アリール炭化水素受容体モジュレーターとしてのピリドピリミジノン誘導体およびその使用 | |
| EP1845970B1 (en) | Tumor necrosis factor inhibitors | |
| JP2013530951A (ja) | ヤヌスキナーゼ阻害剤としてのヘテロ環式化合物 | |
| EP4149629B1 (en) | Purine derivatives as sik-3 inhibitors | |
| KR20150021120A (ko) | 헤테로아릴 화합물 및 이의 이용 방법 | |
| EP4112053A1 (en) | Treatment of synucleinopathies | |
| CN111718350B (zh) | 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用 | |
| US9399644B2 (en) | [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer | |
| HUE033124T2 (en) | New anti-malarial drugs | |
| SA109300406B1 (ar) | ثينيل- وفيرانيل أيزوكوينولينونات وطرق لاستخدامها | |
| EP3049400A1 (en) | New pi3k/akt/mtor inhibitors and pharmaceutical uses thereof | |
| KR20200085815A (ko) | 과증식성 질병의 치료를 위한 카페인산 유도체 | |
| TWI920088B (zh) | Sik-3抑制劑及其用途 | |
| CN120424018A (zh) | 5-氨基-1-取代-1h-1,2,3-三氮唑-4-甲酰胺类化合物及其制备和应用 | |
| WO2019046534A1 (en) | INDOLOQUINOLINE COMPOUNDS DEUTTERED | |
| HK1156310B (en) | Thiazolyl- and oxazolyl-isoquinolinones and methods for using them |